arrow
N

Namiki Izumi

musashino red cross hospital
H指数:79
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds

FIB-4指数和FIB-3指数对慢性肝病中晚期肝纤维化的诊断准确性及年龄特异性阈值

2026-03-030
OAAI
Effect of Pemafibrate on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Multicenter Study

Pemafibrate对代谢功能障碍相关脂肪性肝病的影响:一项全国多中心研究

2025-09-090
OAAI
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment

东亚人种慢性乙型肝炎患者中,Tenofovir Alafenamide (TAF) 和 Tenofovir Disoproxil Fumarate (TDF) 随后转换为 TAF 治疗5年的疗效与安全性。

2025-08-120
OAAI
Human Leukocyte Antigen Genotypes Affect Hepatitis B Virus Mutations Associated With Hepatocellular Carcinoma

人类白细胞抗原基因型影响与肝细胞癌相关的乙型肝炎病毒突变

2025-07-290
PRE
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
2025-02-190
PRE
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
2024-06-060
OAAI
Impact of immune-related adverse events in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
2024-03-175
PRE
The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver diseases (REAL)

新型冠状病毒肺炎对肝癌诊断和治疗的影响: 全国晚期肝病登记处的分析 (REAL)

2024-02-033
OAAI
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease

代谢功能障碍相关性脂肪性肝病与非酒精性脂肪性肝病的一致性

2024-01-1716
PRE
Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
2023-11-1514
OA